Trial Profile
SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- Acronyms SPARE
- 28 Nov 2023 Planned End Date changed from 1 Sep 2021 to 26 Jan 2024.
- 28 Nov 2023 Status changed to active, no longer recruiting.
- 01 Nov 2022 Status changed to completed, according to Results published in the Journal of Neuro-Oncology.